Rickettsia species: (R. aeschlimanii, R. africae, R. australis, R. conorii, R. felis, R. heilongjiangensis, R. helvetica, R. honei, R. japonica, R. monacensis, R. parkerii, R. philipii, R. raoultii, R. sibirica, R. slovaca, R. tamurae)
Authors: Didier Raoult, M.D., Ph.D, Max Maurin, M.D., PhD.
MICROBIOLOGY
Rickettsia species are gram negative, strictly intracellular bacilli, which multiply within the cytosol of endothelial cells. Spotted fever group rickettsiosis now includes 26 validated species, of which 17 are recognized human pathogens Table 1) (43). R. bellii and R. canadensis represent independent groups and are both distributed in the whole American continent (43). They have been detected in several tick species, including Amblyomma, Dermacentor, Haemaphysalis, and Ixodes for R. bellii, and only Haemaphysalis leporispalustris for R. canadensis. R. felis causes the flea typhus of California (40, 44). It is transmitted to humans via cat fleas (Ctenocephalides felis). Although first described in the United States and Mexico, the disease has been reported on all continents (13, 30, 37, 56, 75). Many other Rickettsia species have only been isolated from arthropods, but should be considered potential opportunistic human pathogens (Table 4) (43).
EPIDEMIOLOGY
Ticks are both the vector and the main reservoir of most spotted fever group rickettsiosis (43). Humans are usually infected via the tick-bite or less frequently via the tick hemolymph after crushing the tick. The current knowledge of usual vectors and geographic distributions of spotted fever group rickettsiosis (other than Rocky Mountain spotted fever and Rickettsialpox) are summarized in Table 1. The geographic distribution of each of the Rickettsia species is highly dependent on that of the respective arthropod hosts. In the last decade, new Rickettsia species have been validated, new and old species have been associated for the first time with human infections, and new endemic foci of spotted fever group rickettsiosis have been detected. Moreover, rickettsioses have been recognized as common diseases in travelers returning from endemic areas.
CLINICAL MANIFESTATIONS
Spotted fever group rickettsiosis are clinically characterized by the combination of fever, headache, myalgia, and a cutaneous maculopapular rash involving the entire body including palms and soles (43). An eschar may develop at the site of the tick bite, but remains often unnoticed by the patient, with local lymphadenopathy. Incubation period is usually 4 to 7 days. Truncated clinical presentations are frequent, and a delayed seroconversion in infected patients may lead to delayed diagnosis and antibiotic therapy, and thus more profound illness. More specific clinical presentations include the "scalp eschars and neck lymphadenopathy following tick bites" (SENLAT) syndrome caused by R. slovaca and R. raoultii (14); and the "lymphangitis-associated rikettsiosis" (LAR) syndrome caused by R. sibirica subsp. mongolotimonae (15).
Mediterranean Spotted Fever was first considered a generally benign disease, but severe forms are reported in 6% of patients and mortality may be as high as 2.5 %. Malignant forms may present with petechial rash and may lead to neurological, renal, or cardiac complications. In patients involved with either Israeli spotted fever or Astrakhan fever, a characteristic cutaneous eschar at the site of the tick bite is usually absent. The Siberian Tick Typhus is characterized by a frequent central nervous system involvement. In patients involved with Japanese or Oriental spotted fever an eschar is often present at the site of the vector bite which is, in contrast to other spotted fever group rickettsiosis, often noticeable (31, 68). In Australia, both the Queensland Tick Typhus and the Flinders Island spotted fever are usually mild diseases. An eschar is rarely observed in patients involved with Flinders Island spotted fever, whereas regional lymph node enlargement is common (2, 67). The first documented human infection with R. africae was reported in Zimbabwe in 1992 (27), but the diseases is prevalent in all sub-Saharan Africa (16, 49) and in Guadeloupe in the Caribbean islands (41). African tick bite fever is usually a mild disease, characterized by headache, fever, eschar at the tick-bite site, regional lymphadenopathy, but a cutaneous rash is lacking or very transient in most cases and usually maculo-vesicular. Because several Amblyomma ticks may attack a human simultaneously, the presence of multiple eschars in an infected patient has been reported, and is characteristic of African tick bite fever. The first case of flea borne spotted fever caused by R. felis (previously named as the ELB agent), was described in 1994 in Texas (US) (63). The disease has been more recently characterized on all continents. The first human case of Rickettsia sibirica mongolotimonae infection was documented in Marseille (France), in March 1996, a time of year when Mediterranean Spotted Fever is unlikely (48, 74). This patient presented with a mild disease, with only a few spots on the body and with an inoculation eschar. A second case has been diagnosed in Marseille in 1998 (18), in a patient with fever, cutaneous eschar, and a bipolar rope-like lymphangitis between the cutaneous eschar and a loco-regional lymph node, and thus the disease was named as lymphangitis associated rickettsiosis (LAR) (15). The first documented case of human infection with R. slovaca was reported in 1997 (46). Infected patients typically have a tick-bite on their hair, and present with fever, fatigue, headache, an eschar at the site of the tick-bite, an enlarged cervical lymph node, but no rash. The disease has been named as either TIBOLA (for tick borne lymphadenitis), DEBONEL (for Dermacentor-borne necrosis erythema lymphadenopathy) or more recently SENLAT (for scalp eschars and neck lymphadenopathy following tick bites) (14). New Rickettsia species validated since 2005 and pathogenic for humans include R. heilongjiangensis, R. massiliae, R. philipii, R. raoultii, and R. monacensis Table 1. All are responsible for spotted fever, while R. raoultii is also an etiological agent of SENLAT (17, 42, 51).
LABORATORY DIAGNOSIS
Diagnosis of rickettsial diseases remains based upon serology (10, 29, 43). An antibody response is usually detected only after 10 days from the onset of systemic symptoms, and antibody titers reach a peak after 3 to 4 weeks or later if an antibiotic therapy has been administered. Thus an appropriate antibiotic therapy should be administered upon suspicion of a rickettsial infection, without awaiting for diagnostic confirmation using specific serological tests. Delay in appropriate antibiotic therapy is the main factor for poor prognosis in patients infected with the more severe spotted fever group rickettsial diseases, such as Rocky Mountain spotted fever or Mediterranean spotted fever. Before rickettsial antigens were available for diagnosis, the Weil-Felix test was based on the observation that antibodies from patients recovering from rickettsial infections were able to agglutinate antigens from different Proteus vulgarisstrains (OX-K, OX-2, OX-19). Sera from patients involved with spotted fever group rickettsiosis (except rickettsialpox and Rocky Mountain spotted fever) displayed cross reacting antibodies against Proteus vulgaris OX-2. More recent serological tests use the different Rickettsia species grown in cell cultures as antigen (29). Techniques which have been used include complement fixation tests, microagglutination assays, indirect hemagglutination tests, indirect fluorescent antibody (IFA) tests, and ELISA. IFA remains the current reference, allowing determination of IgG and IgM. Using the IFA test, a single IgG antibody titer of > 128, an IgM titer of > 32, or fourfold increase in antibody titers between acute phase and convalescent phase sera are considered diagnostic. However, serology most often does not allow accurate determination of the Rickettsia species involved. Adsorption assays and western blot may help in such a differentiation. Culture of Rickettsia spp. from clinical samples (mainly blood or a cutaneous eschar biopsy) requires cell culture systems and a level-3 equipped laboratory, and thus is only available in reference laboratories. Sensitivity is low, especially when an appropriate antibiotic therapy has been administered before collecting clinical samples. However, this technique remains essential for isolation and characterization of new Rickettsia species. Direct amplification of rickettsial DNA using PCR and real-time PCR may be obtained from blood (buffy coat), an eschar biopsy, or rarely from other clinical samples (57). This technique may be especially useful early in the course of a rickettsial disease, before an antibody response is detected. More recently, the possibility to detect Rickettsia DNA from skin eschars using cutaneous swabs rather than the more invasive skin biopsy specimens has been emphasized (43).
PATHOGENESIS
Spotted fever group rickettsiae are inoculated to humans through the skin via the bite of ticks (or fleas for R. felis). Endothelial cells are the primary target cells for rickettsiae, leading to a generalized vasculitis. The diversity of the rickettsial microvascular injuries in the infected patient explains the wide spectrum of clinical manifestations and life threatening complications that may be encountered.
SUSCEPTIBILITY IN VITRO AND IN VIVO
Because of their obligate intracellular life-style, susceptibility of rickettsiae to antibiotics cannot be assessed in conventional microbiological tests. Three experimental models have been developed to test the antibiotic susceptibility of rickettsiae: animal models, the embryonated egg model, and cell culture models. Animal models and the embryonated egg model were the first described, however, antibiotic doses used in these models were much higher than those usually used in humans, and therefore it is difficult to extrapolate data to the clinical situation. In vitro infected cell models have been more recently elaborated. These allow more convenient investigation of the antibiotic susceptibility of rickettsiae, and extracellular antibiotic concentrations used in these models may be compared to antibiotic concentrations obtained in human sera.
Single Drug
Animal Models: Guinea pigs and mice were most commonly used as experimental models for spotted fever group rickettsiae to testin vivo antibiotic activity. Rickettsiae were most often injected by the intraperitoneal or intranasal routes, which do not correspond to the natural route of human infection. Antibiotics were administered either orally or subcutaneously. Infection in animals has been assessed by the presence of fever, specific serological response, and death ratio, as compared to untreated infected controls. However, clinical manifestations in infected animals do not reproduce those of human disease and the reliability of animal models for rickettsial infections remains to be established. R. rickettsii, the agent of Rocky Mountain Spotted Fever, was the only spotted fever group rickettsia for which antibiotic susceptibility was evaluated in an animal model, in experiments showing complete protection against fever in infected guinea pigs treated with chlortetracycline (Aureomycin) (73).
Embryonated Egg Model: In the embryonated egg model, rickettsiae were injected into the yolk sac of the eggs. This resulted in death of the embryo usually within a few days following infection. Antibiotics were administered by the same route and usually within the first hour following rickettsial inoculation. Antibiotic activity was deduced from the difference in mean survival time (DMST) of infected embryos receiving antibiotics as compared to infected untreated controls. A rickettsiostatic effect of antibiotics allowed the embryos to survive up to the last day of experiments, usually day 14. The rickettsiacidal activity of antibiotics was assessed by subculture of yolk sacs from surviving eggs at 14 days post infection. Direct smear examination prepared from infected tissues and stained with the Gimenez technique has also been used to evaluate the action of antibiotics. Such a model did not however allow direct evaluation of the growth rate of rickettsiae.
In an early report, Jackson (25) showed that R. conorii was susceptible to chlortetracycline (difference in mean survival time of 2.6 days at 125 µg/egg), and to a lesser extent chloramphenicol (3.8 days difference in mean survival time at 500 µg/egg). More recently, pefloxacin was reported to be rickettsiostatic against R. conorii, with a difference in mean survival time of 2.5 days when using 50 µg/egg (53). Very few data on the antibiotic susceptibility of spotted fever group rickettsiae other than R. rickettsii and R. conorii are available. Streptomycin was not effective against R. orientalis at concentrations up to 20,000 µg/egg (65). Chlortetracycline and chloramphenicol were shown to display a bacteriostatic activity against the South African tick bite fever rickettsia and the North Queensland Tick Typhus rickettsia, with difference in mean survival time (DMST) > 2.5 days for both species, respectively at concentrations > 125 µg/egg for chlortetracycline and > 250 µg/egg for chloramphenicol (25).
Cell Culture Models: The primary target cells for rickettsiae are endothelial cells. However a number of eukaryotic cell lines can be infected with rickettsiae in vitro, including fibroblasts, macrophages, primary chick embryo cells, and human endothelial cells. The plaque formation in infected cell cultures was first used for numeration of viable rickettsiae (34, 35, 70, 71), and then adapted to determine their in vitro antibiotic susceptibility (34, 36, 72). The plaque assay system is currently the recommended technique allowing evaluation of both the bacteriostatic and the bactericidal activity of antibiotics. Cell monolayers (usually Vero cells) grown in tissue culture Petri dishes are acutely infected by rocking incubation with a rickettsial inoculum. Infected cells are then overlaid with Eagle Minimal Essential Medium with 2% fetal calf serum and 0.5 % agar. Antibiotics are added at different concentrations at the same time, whereas no antibiotics are added in drug-free controls. Petri dishes are incubated 4 days at 37°C in a 5% CO2 atmosphere. Cell monolayers are then stained with neutral red dye, allowing visualization of the plaques. The MICs are defined as the lowest antibiotic concentration allowing complete inhibition of plaque formation, as compared to a drug-free growth control. A disk assay was proposed as a convenient modification of the plaque assay. In this model antibiotic disks are placed on the surface of the agar overlay. The diameter of the plaque formation inhibition zone around the antibiotic disk represents a measure of the anti-rickettsial activity of the antibiotic. More recently a microplaque colorimetric assay or dye uptake assay has been described as a more convenient technique allowing accurate and more rapid determination of MICs of several strains of spotted fever group rickettsiae (54). Vero cells cultured in 96-well microtiter plates are infected with 2000 PFU rickettsiae. Antibiotics are added at different concentrations in different rows. Drug-free rows infected with either 2000 PFU, 200 PFU, 20 PFU, or 0 PFU serve as controls. After 4 days incubation of the plates at 37°C in 5% CO2 atmosphere, cell monolayers are washed and neutral red dye is introduced in the wells. The optical density at 492 nm of each well is determined using a spectrophotometer. The MIC corresponds to the lowest antibiotic concentration for which the mean OD at 492 nm is lower than that of the 20 PFU controls. Comparisons between the dye uptake assay and the plaque assay for determination of MICs have given consistent results. A new cell culture system was recently described by Ives et al. (22). Authors determined the inhibition of Rickettsia proliferation, by comparison of rickettsial growth in infected Vero cell cultures incubated in the presence of an antibiotic to that in drug-free controls. Infected cells were revealed by an indirect immunofluorescent antibody method.
A few strains of Rickettsia conorii have been used in in vitro antibiotic susceptibility studies, including Moroccan strain and strain 7 (Table 2). Tetracycline, doxycycline, chloramphenicol, and rifampin were all shown to have bacteriostatic activity (54). Erythromycin and spiramycin were poorly effective with MICs of 4 µg/ml and 16 to 32 µg/ml, respectively (52, 54). More recently clarithromycin was found to rickettsiostatic, with MICs of 2 and 4 µg/ml against R. conorii Moroccan strain (32) and R. conorii strain 7 (22), respectively. Azithromycin, roxithromycin, and dirithromycin were rather less effective with MICs of 16 µg/ml (22). Josamycin remains the most effective macrolide compound tested with a MIC of 1 µg/ml (52). The new ketolide compound, telithromycin, was highly effective in vitro with an MIC of 0.5µg/ml (58). The fluoroquinolone compounds pefloxacin, ofloxacin and ciprofloxacin were shown to be rickettsiacidal, both in the plaque assay and the dye uptake assay (24, 53, 55). Less favorable results have been recently reported by Ives et al. (23), using an IFA test, for ofloxacin and ciprofloxacin. Levofloxacin, the l-isomer of ofloxacin, was demonstrated to be more active than the racemic compound ofloxacin (23, 33). Sparfloxacin was also effective with MICs of 0.25 to 0.5 µg/ml (23, 47).
Only a few studies on in vitro antibiotic susceptibilities of spotted fever group rickettsiae other than R. conorii, R. rickettsii, and R. akari are available (Table 3 and Table 4). The more extensive study has been recently published (59) and include 9 species : R. sibirica, israelian spotted fever rickettsia, R. australis, R. japonica, R. honei, Astrakhan fever rickettsia, R. africae, Rickettsia mongolotimonae, and R. slovaca. Antibiotic susceptibilities were highly homogeneous among the rickettsial species and strains tested. Amoxicillin and gentamicin were poorly effective with MICs ranging from 128 to 256 µg/ml and 4 to 16 µg/ml, respectively. Cotrimoxazole was not effective with MICs > 8/1.6 µg/ml respectively for sulfamethoxazole and trimethoprim, for all the strains tested. Doxycycline was the most effective compound with MICs ranging from 0.06 to 0.125 µg/ml. MICs to thiamphenicol were 0.5 to 2 µg/ml. Erythromycin and pristinamycin were poorly effective with MICs of 2 to 8 µg/ml and 1 to 8 µg/.ml, respectively. MICs to josamycin and clarithromycin ranged from 0.5 to 1 µg/ml and 0.5 to 4 µg/ml, respectively. Fluoroquinolones compounds (pefloxacin, ofloxacin, and ciprofloxacin) were rickettsiostatic with MICs of 0.5 to 2 µg/ml. MICs to rifampin were 0.03 to 1 µg/ml. In the same study, antibiotic susceptibilities of rickettsial species isolated only from arthropods were also tested, including R. bellii, R. canada, R. helvetica, R. conorii M1 strain, R. parkeri, Thai tick typhus rickettsia, strain Bar 29, R. massiliae, R. aeschlimanii, R. montan using, and R. rhipicephali. Although these strains showed antibiotic susceptibility patterns comparable to the rickettsial species previously described, an heterogeneity of susceptibility to rifampin among the different species was shown. Strain Bar 29 (as previously reported (3)), R. massiliae, R. aeschlimanii, R. montanensis, and R. rhipicephali were more resistant to rifampin with MICs > 2 µg/ml. It is of interest to note that all five rickettsial strains belong to a same phylogenetic cluster. Such results led us to speculate that heterogeneity in rifampin susceptibility, among various rickettsial species and in different geographical areas, may explain clinical failures using this antibiotic to treat patients suffering from rickettsial diseases. The activity of the new ketolide compound, telithromycin, has been more recently evaluated against R. africae and for the Israelian tick typhus rickettsia, with an MIC of 0.5µg/ml for both species (58). Recently, R. felis was tested using a new technique including RT-PCR and was found to have a susceptibility comparable to that of other spotted fever (60), especially being erythromycin resistant. This is contradicting early studies (45) resulting from a cell contaminated by R. typhi.
ANTIMICROBIAL THERAPY
Drug of Choice
The conventional antibiotic regimen for spotted fever group rickettsiosis is a 7 to 14 day oral course of doxycycline 200 mg daily (Table 6) (9). Tetracyclines are classically contraindicated in children less than 8 years old because of the possibility of tooth discoloration (66). However, because it's the most effective treatment of rickettsioses, doxycycline should be used in young children with severe diseases (43). The tetracyclines are contraindicated during pregnancy. They may be toxic to the fetus, including bone toxicity and discoloration of deciduous teeth when given after the 16th week of gestation (66). Tetracyclines have also been reported to cause serious hepatotoxicity, often with pancreatitis, in pregnant women (20). These antibiotics may also induce gastric intolerance and photosensitization as general side effects (66). Short course therapy with doxycycline (100 mg twice daily for 1 to 2 days) has been reported to be effective for Rocky Mountain spotted fever (21) and Mediterranean Spotted Fever (5, 6). As compared to conventional antibiotic regimen, the short- course regimen presents the advantages of being well tolerated in almost all patients and cost effective. It may represent an effective and safe alternative in children less than 8 years old, preventing the occurrence of tooth discoloration. The use of a tetracycline even for short duration remains more problematic in the pregnant woman and cannot be currently encouraged.
Monotherapy or Combination Therapy
Antibiotic combinations have not been tested against rickettsiae in vitro. To date, no antibiotic combination has been shown to be superior in vivo to doxycycline alone. Combination therapy is not indicated in common clinical presentations of spotted fever group rickettsiosis. In severely ill patients, early administration of doxycycline before definite diagnosis is made is critical.
Special Situations
In severely diseased patients, doxycycline should be administered first by the intravenous route at 200 mg daily, and a prolonged duration up to three days following apyrexia should be considered. There is no clinical indication that other drugs should be more effective than tetracycline, even in patients with neurological complications.
Alternative Therapy
Randomized clinical trials comparing various antibiotic regimens for Mediterranean spotted fever are summarized in Table 5. These alternative therapies are summarized in Table 6. Chloramphenicol (administered for at least 1 week) has long been considered the main alternative for rickettsial infections. However, chloramphenicol presents the potential risk of aplastic anemia, acute hemolytic anemia in patients with the Mediterranean form of glucose-6-phosphate dehydrogenase (G6PD) deficiency, and is contraindicated in the pregnant woman. Moreover, recent in vitro and in vivo data indicate that chloramphenicol is much less effective than tetracyclines. Prognosis in children involved with of Rocky Mountain spotted fever is significantly worse when chloramphenicol rather than a tetracycline has been administered (21). Relapse was reported in an Israeli patient suffering Mediterranean Spotted Fever who died despite completion of the chloramphenicol therapy (64). Fluoroquinolones, including pefloxacin, ofloxacin, and ciprofloxacin have been first reported to be effective for the treatment of Mediterranean Spotted Fever (7, 19, 26, 50, 55). A 10 to 15 day oral regimen of either 200 mg bid of ofloxacin, 400 mg bid pefloxacin, or 500 mg bid of ciprofloxacin has been recommended. Shorter duration of antibiotic therapy was used with ciprofloxacin (55). A 2 day regimen of 500 mg bid of ciprofloxacin was compared to a 2 day course of doxycycline 200mg daily. All patients treated with ciprofloxacin resolved. However, apyrexia was delayed in the short-term ciprofloxacin therapy group as compared to the doxycycline group. More recently, the administration of a fluoroquinolone has been associated with poor outcome in patients suffering from Mediterranean spotted fever, and deleterious effects in R. conorii-infected cell culture models supposedly because of the upregulation of of a toxin-antitoxin module (1, 8). Although these observations should be confirmed by further clinical data, they should be taken into account when treating patients involved with spotted fevers using fluoroquinolones. As for tetracyclines, fluoroquinolones are contraindicated in the child and the pregnant woman. Among the macrolides, erythromycin is not considered a safe alternative for Mediterranean Spotted Fever (39). Following in vitro studies, josamycin has been proposed as a possible alternative to tetracyclines. The usefulness of josamycin has been assessed in a randomized trial for antibiotic therapy of Mediterranean Spotted Fever, both in adults and children (5). Josamycin 1g tid orally (50 mg/kg of body weight bid in children) was as active as the single day therapy with doxycycline (200mg bid for adults, 5mg/ kg of body weight in children). The clinical efficacy of clarithromycin (15mg/kg/day orally for 7 days) as compared to chloramphenicol (50mg/kg/day orally for 7 days) was recently assessed in a randomized control trial in 51 children with Mediterranean spotted fever (12). Mean time to defervescence were respectively 36.7h with clarithromycin and 47.1h with chloramphenicol. Azithromycin (10mg/kg/day orally for 3days) has also been evaluated comparatively to doxycycline (5mg/kg/day orally for 5 days) in 30 children with Mediterranean spotted fever (38), and both regimens had equal efficacy. More recently, azithromycin and clarithromycin were comparatively evaluated in 97 children suffering from Mediterranean spotted fever (11), with comparable efficacy. The mean time (+/- SD) to defervescence was 46.2 +/- 36.4 h in the clarithromycin-treated group and 39.3 +/- 31.3 h in the azithromycin-treated group. Thus, josamycin (50mg/Kg/d in two divided doses, for 7 days) and the newer macrolide compounds azithromycin (10mg/Kg/d in 1 dose for 3-5 days) and clarithromycin (15mg/Kg/d in 2 divided doses for 7 days), which have superior in vitro activity against rickettsiae as compared to erythromycin, may represent a current safe alternative to tetracyclines in children less than 8 years old. Josamycin may also represent a safe alternative to tetracyclines in the pregnant woman, but clinical data are lacking. Recently, Cascio et al. (12) reported a successful outcome in a 20-year old woman with in the 13th week of gestation who was treated with the combination of erythromycin and rifampin for Mediterranean spotted fever.
Cotrimoxazole is not useful to treat rickettsioses, and potentially may worsen the outcome of the disease (61). In vitro, isolation of spotted fever group rickettsiae from ticks was obtained in cell culture systems despite adding cotrimoxazole in the culture medium (28). A regimen of rifampin (10mg/kg bid for 5 days) was compared to the one day doxycycline therapy schedule, in the region of Catalonia, in Spain (4). Outcome was favorable in both groups. However, delayed apyrexia was noticed in patients receiving rifampin. Moreover 4 patients become apyretic only after 5 days therapy which is comparable to usual time of spontaneous fever resolution. In one patient rifampin therapy was considered a failure and was changed for doxycycline. Failures in patients with Mediterranean Spotted Fever in Catalonia (Spain) after treatment with rifampin has been tentatively correlated with recent isolation of rickettsial strains with natural resistance to this antibiotic (R. massiliae) from Rhipicephalus ticks in this region (3). This rickettsiae have been found recently to be human pathogens (69). It may be hypothesized that the existence of rifampin-resistant rickettsiae in some areas may explain therapy failures when using this antibiotic, as well as contradictory reports from different areas on the effectiveness of rifampin to treat rickettsial diseases. More isolates are needed to resolve this hypothesis.
VACCINE
There are no vaccines available for Rickettsia spotted fever.
REFERENCES
1. Audoly G, Vincentelli R, Edouard S, Georgiades K, Mediannikov O, Gimenez G, Socolovschi C, Mège JL, Cambillau C, Raoult D. Effect of rickettsial toxin VapC on its eukaryotic host. PloS One 2011; 6:e26528. [PubMed]
2. Baird RW, Lloyd M, Stenos J, Ross BC, Stewart RS, Dwyer B. Characterization and comparison of Australian human spotted fever group rickettsiae. J Clin Microbiol 1992; 30:2896–2902. [PubMed]
3. Beati L, Roux V, Ortuño A, Castella J, Segura Porta F, Raoult D. Phenotypic and genotypic characterization of spotted fever group rickettsiae isolated from Catalan Rhipicephalus sanguineus ticks. J Clin Microbiol 1996;34:2688-2694. [PubMed]
4. Bella F, Espejo E, Uriz S, Serrano JA, Alegre MD, Tort J. Randomized trial of five-day rifampin versus one-day doxycycline therapy for Mediterranean spotted fever. J Infect Dis 1991;164:433. [PubMed]
5. Bella F, Font B, Uriz S, Munoz T, Espejo E, Traveria J, Serrano JA, Segura F. Randomized trial of doxycycline versus josamycin for Mediterranean spotted fever. Antimicrob Agents Chemother 1990;34:937-938. [PubMed]
6. Bella-Cueto F, Font-Creus B, Segura-Porta F, Espejo-Arenas E, Lopez-Pares P, Munoz-Espin T. Comparative, randomized trial of one-day doxycycline versus 10- day tetracycline therapy for Mediterranean spotted fever. J Infect Dis 1987;155:1056-1058. [PubMed]
7. Bernard E, Carles M, Politano S, Laffont C, Dellamonica P. Rickettsiosis caused by Rickettsia conorii: treatment by ofloxacin. Rev Infect Dis 1989;11 Suppl. 5:S989.
8. Botelho-Nevers E, Edouard S, Leroy Q, Raoult D. Deleterious effect of ciprofloxacin on Rickettsia conorii-infected cells is linked to toxin-antitoxin module up-regulation. J Antimicrob Chemother 2012;67:1677–1682. [PubMed]
9. Botelho-Nevers E, Socolovschi C, Raoult D, Parola P. Treatment of Rickettsia spp. infections: a review. Expert Rev Anti Infect Ther 2012; 10:1425–1437. [PubMed]
10. Boyd AS. Rickettsialpox. Dermatol Clin 1997;15:313-318. [PubMed]
11. Cascio A, Colomba C, Antinori S, Paterson DL, Titone L. Clarithromycin versus azithromycin in the treatment of Mediterranean spotted fever in children: a randomized controlled trial. Clin Infect Dis 2002;34:154-158. [PubMed]
12. Cascio A, Colomba C, Di Rosa D, Salsa L, di Martino L, Titone L. Efficacy and safety of clarithromycin as treatment for Mediterranean spotted fever in children: a randomized controlled trial. Clin Infect Dis 2001; 33:409-411. [PubMed]
13. Dittrich S, Phommasone K, Anantatat T, Panyanivong P, Slesak G, Blacksell SD, Dubot-Pérès A, Castonguay-Vanier J, Stenos J, Newton PN, Paris DH. Rickettsia felis Infections and comorbid conditions, Laos, 2003-2011. Emerg Infect Dis 2014; 20:1402–1404. [PubMed]
14. Dubourg G, Socolovschi C, Del Giudice P, Fournier PE, Raoult D. Scalp eschar and neck lymphadenopathy after tick bite: an emerging syndrome with multiple causes. Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol 2014; 33:1449–1456. [PubMed]
15. Fournier P-E, Gouriet F, Brouqui P, Lucht F, Raoult D. Lymphangitis-associated rickettsiosis, a new rickettsiosis caused by Rickettsia sibirica mongolotimonae: seven new cases and review of the literature. Clin Infect Dis. 2005; 40:1435-1444. [PubMed]
16. Fournier PE, Roux V, Caumes E, Donzel M, Raoult D. Outbreak of Rickettsia africae infections in participants of an adventure race in South Africa. Clin Infect Dis 1998;27:316-323. [PubMed]
17. Fournier PE, Roux V, Raoult D. Phylogenetic analysis of spotted fever group rickettsiae by study of the outer surface protein rOmpA. Int J Syst Bacteriol. 1998; 48:839-849. [PubMed]
18. Fournier PE, Tissot-Dupont H, Gallais H, Raoult DR. Rickettsia mongolotimonae: a rare pathogen in France. Emerg Infect Dis 2000;6:290-292. [PubMed]
19. Gudiol F, Pallares R, Carratala J, Bolao F, Ariza J, Rufi G, Viladrich RF. Randomized double-blind evaluation of ciprofloxacin and doxycycline for Mediterranean spotted fever. Antimicrob Agents Chemother 1989;33:987. [PubMed]
20. Herbert WN, Seeds JW, Koontz WL, Cefalo RC. Rocky Mountain spotted fever in pregnancy: differential diagnosis and treatment. Southern Med J 1982; 75:1063-1066. [PubMed]
21. Holman RC, Paddock CD, Curns AT, Krebs JW, McQuiston JH, Childs JE. Analysis of risk factors for fatal Rocky Mountain Spotted Fever: evidence for superiority of tetracyclines for therapy. J Infect Dis 2001;184:1437-1444.[PubMed]
22. Ives TJ, Manzewitsch P, Regnery RL, Butts JD, Kebede M. In vitro susceptibilities of Bartonella henselae, B. quintana, B. elizabethae, Rickettsia rickettsii, R. conorii, R. akari, and R. prowazekii to macrolide antibiotics as determined by immunofluorescent-antibody analysis of infected Vero cell monolayers. Antimicrob Agents Chemother 1997;41:578-582. [PubMed]
23. Ives TJ, Marston EL, Regnery RL, Butts JD. In vitro susceptibilities of Bartonella and Rickettsia spp. to fluoroquinolone antibiotics as determined by immunofluorescent antibody analysis of infected Vero cell monolayers. Int J Antimicrob Agents 2001;18:217-222. [PubMed]
24. Jabarit-Aldighieri N, Torres H, Raoult D. Susceptibility of R.conorii, R.rickettsii and C. burnetii to CI- 960 (PD 127,391), PD 131,628, pefloxacin, ofloxacin and ciprofloxacin. Antimicrob Agents Chemother 1992;36:2529-2532.[PubMed]
25. Jackson EB. Comparative efficacy of several antibiotics on experimental rickettsial infections in embryonated eggs. Antibiotics Chemother 1951;1:231-241.
26. Janbon F, Jonquet O, Reynes J, Bertrand A. Use of pefloxacin in the treatment of rickettsiosis and coxiellosis. Rev Infect Dis 1989; 11 suppl. 5:990-991.
27. Kelly P, Matthewman L, Beati L, Raoult D, Mason P, Dreary M, Makombe R. African tick-bite fever - a new spotted fever group rickettsiosis under an old name. Lancet 1992;340:982-983. [PubMed]
28. Kelly PJ, Raoult D, Mason PR. Isolation of spotted fever group rickettsias from triturated ticks using a modification of the centrifugation-shell vial technique. Trans Roy Soc Trop Med Hyg 1991;85:397-398. [PubMed]
29. La Scola B, Raoult D. Laboratory diagnosis of rickettsioses: current approaches to diagnosis of old and new rickettsial diseases. J Clin Microbiol 1997;35:2715-2727. [PubMed]
30. Lim MY, Brady H, Hambling T, Sexton K, Tompkins D, Slaney D. Rickettsia felis infections, New Zealand. Emerg Infect Dis 2012;18:167–169. [PubMed]
31. Mahara F. Japanese spotted fever: report of 31 cases and review of the literature. Emerg Infect Dis 1997;3:105-111. [PubMed]
32. Maurin M, Raoult D. In vitro susceptibilities of spotted fever group rickettsiae and Coxiella burnetii to clarithromycin. Antimicrob Agents Chemother 1993;37:2633-2637. [PubMed]
33. Maurin M, Raoult D. Bacteriostatic and bactericidal activity of levofloxacin against Rickettsia rickettsii, Rickettsia conorii, "Israeli spotted fever group rickettsia" and Coxiella burnetii. J Antimicrob Chemother 1997;39:725-730. [PubMed]
34. McDade JE. Determination of antibiotic susceptibility of Rickettsia by the plaque assay technique. Appl Microbiol 1969;18:133-135. [PubMed]
35. McDade JE, Gerone PJ. Plaque assay for Q fever and scrub typhus rickettsiae. Appl Microbiol 1970;19:963-965.[PubMed]
36. McDade JE, Stakebake JR, Gerone PJ. Plaque assay system for several species of Rickettsia. J Bacteriol 1969;99:910-912. [PubMed]
37. Mediannikov O, Socolovschi C, Edouard S, Fenollar F, Mouffok N, Bassene H, Diatta G, Tall A, Niangaly H, Doumbo O, Lekana-Douki JB, Znazen A, Sarih M, Ratmanov P, Richet H, Ndiath MO, Sokhna C, Parola P, Raoult D. Common epidemiology of Rickettsia felis infection and malaria, Africa. Emerg Infect Dis 2013; 19:1775–1783. [PubMed]
38. Meloni G, Meloni T. Azithromycin vs. doxycycline for Mediterranean spotted fever. Pediat Inf Dis J 1996;15:1042-1044. [PubMed]
39. Munoz Espin T, Lopez Pares P, Espejo Arenas E, Font Creus B, Martinez Vila I, Traveria Casanova J, Segura-Porta F, Bella-Cueto F. Erythromycin versus tetracycline for treatment of Mediterranean spotted fever. Arch Dis Child 1986;61:1027-1029.[PubMed]
40. Parola P. Rickettsia felis: from a rare disease in the USA to a common cause of fever in sub-Saharan Africa. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis 2011;17:996–1000. [PubMed]
41. Parola P, Jourdan J, Raoult D. Tick-borne infection caused by Rickettsia africae in the West Indies. N Engl J Med 1998;338:1391. [PubMed]
42. Parola P, Paddock CD, Raoult D. Tick-borne rickettsioses around the world: emerging diseases challenging old concepts. Clin Microbiol Rev. 2005;18:719-756. [PubMed]
43. Parola P, Paddock CD, Socolovschi C, Labruna MB, Mediannikov O, Kernif T, Abdad MY, Stenos J, Bitam I, Fournier PE, Raoult D. Update on tick-borne rickettsioses around the world: a geographic approach. Clin Microbiol Rev 2013; 26:657–702. [PubMed]
44. Pérez-Osorio CE, Zavala-Velázquez JE, Arias León JJ, Zavala-Castro JE. Rickettsia felis as emergent global threat for humans. Emerg Infect Dis 2008;14:1019–1023. [PubMed]
45. Radulovic S, Higgins JA, Jaworski DC, Azad AF. In vitro and in vivo antibiotic susceptibilities of ELB rickettsiae. Antimicrob Agents Chemother. 1995;39:2564-2566. [PubMed]
46. Raoult D, Berbis P, Roux V, Xu W, Maurin M. A new tick-transmitted disease due to Rickettsia slovaca. Lancet 1997;350:112-113. [PubMed]
47. Raoult D, Bres P, Drancourt M, Vestris G. In vitro susceptibilities of Coxiella burnetii, Rickettsia rickettsii, and Rickettsia conorii to the fluoroquinolone Sparfloxacin. Antimicrob Agents Chemother 1991;35:88-91. [PubMed]
48. Raoult D, Brouqui P, Roux V. A new spotted-fever-group Rickettsiosis. Lancet 1996;348:412. [PubMed]
49. Raoult D, Fournier PE, Fenollar F, Jensenius M, Prioe T, de Pina JJ, Caruso G, Jones N, Laferl H, Rosenblatt JE, Marrie TJ. Rickettsia africae, a tick-borne pathogen in travelers to sub-Saharan Africa. N Engl J Med 2001;344:1504-1510. [PubMed]
50. Raoult D, Gallais H, de Micco P, Casanova P. Ciprofloxacin therapy for Mediterranean spotted fever. Antimicrob Agents Chemother 1986;30:606-607. [PubMed]
51. Raoult D, Lakos A, Fenollar F, Beytout J, Brouqui P, Fournier PE. Spotless rickettsiosis caused by Rickettsia slovaca and associated with Dermacentor ticks. Clin Infect Dis. 2002 May 15;34:1331-1336. [PubMed]
52. Raoult D, Roussellier P, Tamalet J. In vitro evaluation of josamycin, spiramycin, and erythromycin against Rickettsia rickettsii and R. conorii. Antimicrob Agents Chemother 1988;32:255-256. [PubMed]
53. Raoult D, Roussellier P, Vestris G, Galicher V, Perez R, Tamalet J. Susceptibility of Rickettsia conorii and R. rickettsii to pefloxacin, in vitro and in ovo. J Antimicrob Chemother 1987;19:303-305. [PubMed]
54. Raoult D, Roussellier P, Vestris G, Tamalet J. In vitro antibiotic susceptibility of Rickettsia rickettsii and Rickettsia conorii: plaque assay and microplaque colorimetric assay. J Infect Dis 1987;155:1059-1062. [PubMed]
55. Raoult D, Zuchelli P, Weiller PJ, Charrel C, San Marco JL, Gallais H, Casanova P. Incidence, clinical observations and risk factors in the severe form of Mediterranean spotted fever among patients admitted to hospital in Marseilles 1983-1984. J Infection 1986;12:111-116. [PubMed]
56. Renvoisé A, Joliot AY, Raoult D. Rickettsia felis infection in man, France. Emerg Infect Dis 2009; 15:1126–1127. [PubMed]
57. Renvoisé A, Rolain J-M, Socolovschi C, Raoult D. Widespread use of real-time PCR for rickettsial diagnosis. FEMS Immunol Med Microbiol 2012;64:126–129. [PubMed]
58. Rolain JM, Maurin M, Bryskier A, Raoult D. In vitro activities of telithromycin (HMR 3647) against Rickettsia rickettsii, Rickettsia conorii, Rickettsia africae, Rickettsia typhi, Rickettsia prowazekii, Coxiella burnetii, Bartonella henselae, Bartonella quintana, Bartonella bacilliformis, and Ehrlichia chaffeensis. Antimicrob Agents Chemother 2000; 44:1391-1393. [PubMed]
59. Rolain JM, Maurin M, Vestris G, Raoult D. In vitro susceptibilities of 27 rickettsiae to 13 antimicrobials. Antimicrob Agents Chemother 1998;42:1537-1541. [PubMed]
60. Rolain JM, Stuhl L, Maurin M, Raoult D. Evaluation of antibiotic susceptibilities of three rickettsial species including Rickettsia felis by a quantitative PCR DNA assay. Antimicrob Agents Chemother. 2002;46:2747-2751. [PubMed]
61. Ruiz Beltran R, Herrero Herrero JI. Deleterious effect of trimethoprim-sulfamethoxazole in Mediterranean Spotted Fever (letter). Antimicrob Agents Chemother 1992; 36:1342-1344. [PubMed]
62. Ruiz Beltran R, Herrero-Herrero JI. Evaluation of Ciprofloxacin and Doxycycline in the treatment of Mediterranean Spotted Fever. Eur J Clin Microbiol Infect D 1992;11:427-431. [PubMed]
63. Schriefer ME, Sacci JB, Dumler JS, Bullen MG, Azad AF. Identification of a novel rickettsial infection in a patient diagnosed with murine typhus. J Clin Microbiol 1994;32:949-954. [PubMed]
64. Shaked Y, Samra Y, Maier MK, Rubinstein E. Relapse of rickettsial Mediterranean spotted fever and murine typhus after treatment with chloramphenicol. J Infection 1989;18:35-37. [PubMed]
65. Smadel JE, Jackson EB, Gauld RL. Factors influencing the growth of rickettsiae. I. Rickettsiostatic effect of streptomycin in experimental infections. J Immunol 1947;57:273-284. [PubMed]
66. Smilack JD. The tetracyclines. Mayo Clin Proc 1999;74:727-729. [PubMed]
67. Stewart RS. Flinders Island spotted fever : a newly recognized endemic focus of tick typhus in Bass Strait. Part 1. Clinical and epidemiological features. Med J Australia 1991;154:94-99. [PubMed]
68. Uchida T. Rickettsia japonica, the etiologic agent of Oriental spotted fever. Microbiol Immunol 1993;37:91-102. [PubMed]
69. Vitale G, Mansuelo S, Rolain JM, Raoult D. Rickettsia massiliae human isolation. Emerg Infect Dis. 2006;12:174-175. [PubMed]
70. Weinberg EH, Stakebake JR, Gerone PJ. Plaque assay for Rickettsia rickettsii. J Bacteriol 1969;98:398-402. [PubMed]
71. Wike DA, Tallent G, Peacock MG, Williams JC. Studies of the rickettsial plaque assay technique. Infect Immun 1972;5:715-722. [PubMed]
72. Wisseman CL, Waddell AD, Walsh WT. In vitro studies of the action of antibiotics on Rickettsia prowazekii by two basic methods of cell culture. J Infect Dis 1974;130:564-574. [PubMed]
73. Wong SC, Cox HR. Action of aureomycin against experimental rickettsial and viral infections. Ann NY Acad Sci 1948;51:290-305. [PubMed]
74. Yu X, Fan M, Xu G, Liu Q, Raoult D. Genotypic and antigenic identification of two news strains of spotted fever group Rickettsiae isolated from China. J Clin Microbiol 1993;31:83-88. [PubMed]
75. Zhang J, Lu G, Kelly P, Zhang Z, Wei L, Yu D, Kayizha S, Wang C. First report of Rickettsia felis in China. BMC Infect Dis 2014; 14:682. [PubMed]
Tables
Table 1. Tick-borne spotted fever group rickettsiosis other than Rocky Mountain Spotted Fever (caused by R. rickettsii), and rickettsialpox (caused by R. akari) which are presented in specific chapters.| Rickettsia sp. | Syndrome | Potential vectors | Distribution* |
|---|---|---|---|
| R. aeschlimanii | Spotted fever | Amblyomma,Ripicephalus, Hyalomma, Haemaphysalis | Africa, Asia, Europe |
| R. africae | African tick bite fever | Amblyomma,Ripicephalus, Hyalomma | Africa, North and Central America, Asia, Pacific Islands |
| R. australis | Queensland tick typhus | Ixodes | Australia |
| R. conorii subsp. conorii | Mediterranean spotted fever | Rhipicephalus sanguineus | Europe, Africa, Asia |
| R. conorii subsp. caspia | Astrakhan fever | Rhipicephalus | Europe, sub-Saharan Africa |
| R. conorii subsp. indica | Indian tick typhus | Rhipicephalus sanguineus | Europe, Asia |
| R. conorii subsp. israelensis | Israeli tick typhus | Rhipicephalus sanguineus | Europe, Asia, North Africa |
| R. heilongjiangensis | Far-Eastern spotted fever | Haemaphysalis, Dermacentor | Asia |
| R. helvetica | Ixodes | Asia (Laos, Thailand), Europe, North Africa | |
| R. honei | Flinders Island spotted fever | Ixodes, Bothriocroton hydrosauri | Asia, Australia, Pacific |
| R. japonica | Japanese spotted fever | Haemaphysalis, Ixodes, Dermacentor | Asia |
| R. massiliae | Spotted fever | Rhipicephalus, Ixodes, Haemaphysalis | America, Asia, Africa, Europe |
| R. monacensis | Spotted fever | Ixodes | Europe, North Africa |
| R. parkeri | Spotted fever | Amblyomma, Dermacentor | America |
| R. philipii | Spotted fever | Dermacentor occidentalis | North and central America |
| R. raoultii | SENLAT$ | Dermacentor, Ixodes, Haemaphysalis, Amblyomma | Europe, Asia |
| R. sibirica subsp. mongolotimonae | LAR£ | Hyalomma, Rhipicephalus | Europe, Asia, sub-Saharan Africa |
| R. sibirica subsp. sibirica | Siberian tick typhus | Dermacebtor, Haemaphysalis, Ixodes | Asia |
| R. slovaca | SENLAT | Dermacentor | Europe, Asia, North Africa |
| R. tamurae | Spotted fever | Amblyomma testudinarium | Asia |
*. Known geographic distribution of species, with or without reported human
infections.
$. SENLAT: scalp eschars and neck lymphadenopathy following tick bites
£. LAR: lymphangitis-associated rikettsiosis
Table 2. In Vitro antibiotic susceptibility of R. conorii. MICs (mg/L) are presented for R. conorii Moroccan (ATCC VR-141) and Seven (ATCC VR-613) strains as determined by using the plaque assay and the dye uptake assay, and for R. conorii Seven as determined by using an indirect fluorescent antibody (IFA) test.
| Antibiotics | MICs in cell cultures (mg/L) | References | |||
|---|---|---|---|---|---|
| Plaque assay | Dye uptake | IFA test | Strain | ||
| amoxicillin | 128 | 128 | Moroccan | (59) | |
| 128 | 128 | 7 | (59) | ||
| gentamicin | 8 | 8 | Moroccan | (59) | |
| 8 | 8 | 7 | (59) | ||
| chloramphenicol | 0.5 | 0.25 | Moroccan | (54) | |
| thiamphenicol | 1 | 2 | Moroccan | (59) | |
| 1 | 2 | 7 | (59) | ||
| tetracycline | 0.25 | 0.25 | Moroccan | (54) | |
| doxycycline | 0.06 | 0.12 | Moroccan | (54) | |
| 0.06 | 0.125 | 7 | (59) | ||
| erythromycin | 4 | 4 | Moroccan | (54) | |
| 8 | 8 | 7 | (59) | ||
| 8 | 7 | (22) | |||
| spiramycin | 16 | 32 | Moroccan | (52) | |
| josamycin | 1 | 1 | Moroccan | (52) | |
| 0.5 | 0.5 | 7 | (59) | ||
| pristinamycin | 2 | 2 | Moroccan | (59) | |
| 2 | 1 | 7 | (59) | ||
| clarithromycin | 2 | 2 | Moroccan | (32) | |
| 1 | 1 | 7 | (59) | ||
| 4 | 7 | (22) | |||
| azithromycin | 16 | 7 | (22) | ||
| dirithromycin | 16 | 7 | (22) | ||
| roxithromycin | 16 | 7 | (22) | ||
| telithromycin | 0.5 | Moroccan | (58) | ||
| rifampin | 0.25 | 0.25 | Moroccan | (54) | |
| 0.125 | 0.125 | 7 | (59) | ||
| ciprofloxacin | 0.25 | 0.25 | Moroccan | (54) | |
| 0.5 | 0.5 | 7 | (59) | ||
| 16.3 | 7 | (23) | |||
| ofloxacin | 1 | Moroccan | (24) | ||
| 1 | 1 | 7 | (59) | ||
| 5.2 | 7 | (23) | |||
| pefloxacin | 1 | 0.5 | Moroccan | (53) | |
| 0.5 | 1 | 7 | (59) | ||
| sparfloxacin | 0.25 | 0.5 | Moroccan | (47) | |
| 1.1 | 7 | (23) | |||
| levofloxacin | 1.6 | 7 | (23) | ||
| sulfamethoxazole | >8 | >8 | Moroccan | (59) | |
| >8 | >8 | 7 | (59) | ||
Table 3. In Vitro antibiotic susceptibility of Spotted Fever Group Rickettsiae other than R. rickettsii, R. conorii, and R. akari. Minimum Inhibitory Concentrations (mg/L) as determined in the plaque assay are summarized (59).
| Strain | Doxy | Thiam | Rifam | Ery | Clar | Josa | Prist | Cip | Ofl | Pef |
|---|---|---|---|---|---|---|---|---|---|---|
| R. conorii serotype Israeli | 0.06 | 1 | 0.5 | 4 | 1 | 0.5 | 1 | 0.5 | 1 | 1 |
| R. conorii serotype Astrakhan (A-167) | 0.06 | 0.5 | 0.03 | 8 | 0.5 | 0.5 | 2 | 0.5 | 0.5 | 0.5 |
| R. sibirica (246) | 0.06 | 0.5 | 0.06 | 2 | 2 | 1 | 2 | 1 | 1 | 1 |
| R. australis (Phillips) | 0.06 | 2 | 0.125 | 8 | 4 | 0.5 | 2 | 0.5 | 1 | 1 |
| R. japonica (YM) | 0.125 | 1 | 0.25 | 8 | 1 | 1 | 8 | 1 | 1 | 1 |
| R. honei (RB) | 0.06 | 2 | 0.5 | 4 | 1 | 0.5 | 2 | 1 | 1 | 1 |
| R. africae (ESF-5) | 0.125 | 1 | 0.125 | 8 | 2 | 0.5 | 2 | 0.5 | 1 | 1 |
| R. "mongolotimonae" | 0.125 | 1 | 0.125 | 8 | 4 | 1 | 2 | 1 | 1 | 1 |
| R. slovaca (13-B) | 0.06 | 1 | 0.5 | 2 | 0.5 | 1 | 1 | 1 | 1 | 1 |
Doxy : doxycycline; Thiam : thiamphenicol; Rifam : rifampin; Ery : erythromycin; Clar : clarithromycin; Josa : josamycin; Prist : pristinamycin; Cip : ciprofloxacin; Ofl : ofloxacin; Pef : pefloxacin.
Table 4. In vitro antibiotic susceptibility of Rickettsiae isolated only from ticks. Minimum Inhibitory Concentrations (mg/L) as determined in the plaque assay are summarized (59).
| Strain | Doxy | Thiam | Rifam | Ery | Clar | Josa | Prist | Cip | Ofl | Pef |
|---|---|---|---|---|---|---|---|---|---|---|
| R. bellii (369L42-1) | 0.125 | 0.5 | 0.06 | 4 | 4 | 1 | 2 | 0.5 | 0.5 | 1 |
| R. canada (2678) | 0.06 | 1 | 0.125 | 4 | 1 | 1 | 2 | 0.5 | 0.5 | 1 |
| R. helvetica (C9P9) | 0.125 | 1 | 0.06 | 2 | 1 | 0.5 | 2 | 0.25 | 0.5 | 1 |
| R. parkeri (Maculatum) | 0.25 | 4 | 0.25 | 4 | 1 | 0.5 | 2 | 0.25 | 0.25 | 0.5 |
| Thai tick typhus rickettsia | 0.06 | 2 | 0.125 | 8 | 1 | 1 | 4 | 0.5 | 2 | 1 |
| strain Bar 29 | 0.06 | 1 | 2 | 4 | 2 | 0.5 | 4 | 0.25 | 0.5 | 0.5 |
| R. massiliae | 0.06 | 1 | 2 | 2 | 1 | 1 | 1 | 0.25 | 0.5 | 0.5 |
| R. aeschlimanii | 0.06 | 1 | 2 | 8 | 1 | 0.5 | 2 | 0.5 | 0.5 | 1 |
| R. montana (ATCC VR-611) | 0.125 | 2 | 2 | 8 | 1 | 2 | 4 | 1 | 1 | 1 |
| R. rhipicephali | 0.25 | 1 | 2 | 4 | 1 | 1 | 2 | 1 | 1 | 1 |
Doxy : doxycycline; Thiam : thiamphenicol; Rifam : rifampin; Ery : erythromycin; Clar : clarithromycin; Josa : josamycin; Prist : pristinamycin; Cip : ciprofloxacin; Ofl : ofloxacin; Pef : pefloxacin
Table 5. Summary of randomized clinical trials of antibiotic therapy for Mediterranean Spotted Fever
| Drugs and regimens | n° of patients | Results | references |
|---|---|---|---|
| doxycycline, 1 day (200mg two times) vs. tetracycline, 10 days (500mg qid) | 70 | NS | (6) |
| clarithromycin, 7 days (7.5 mg bid) vs. chloramphenicol, 7 days (12.5mg/kg qid) | 46 | more rapid defervescence with clarithromycin | (12) |
| erythromycin, 10 days (12.5mg/kg qid) vs. tetracycline, 10 days (10 mg/kg qid) | 81 | more rapid disappearance of fever and symptoms with tetracycline | (39) |
| azithromycin, 3days (10 mg/kg once daily) vs. doxycycline, 5 days (5mg/kg once daily) | 30 | NS | (38) |
| josamycin, 5 days (25 mg/kg bid) vs. doxycycline, 1 day (2.5 mg/kg bid) | 59 | NS | (5) |
| azithromycin, 3 days (10 mg/kg once daily) vs. clarithromycin, 7 days (7.5 mg/kg bid) | 87 | NS | (11) |
| ciprofloxacin, 2 days (500mg bid) vs. doxycycline, 2 days (100mg bid) | 43 | more rapid disappearance of fever and symptoms with doxycycline | (19) |
| ciprofloxacin, 7 days (750mg bid) vs. doxycycline, 7 days (100mg bid) | 70 | NS | (62) |
| rifampin, 5 days (10mg/kg bid) vs. doxycycline, 1 day (200mg two times) | 32 | more rapid disappearance of fever with doxycycline | (4) |
NS: no statistically significant differences in time to disappearance of fever and symptoms
Table 6. Recommendations for antibiotic treatment of Spotted Fever Group Rickettsiosis other than Rocky Mountain Spotted Fever (due to R. rickettsii), and rickettsialpox (due to R. akari) which are presented in specific chapters.
| Condition | antibiotic | Dose | duration | References |
|---|---|---|---|---|
| spotted fever group rickettsiosis in adult and in child > 8 years | 1. doxycycline | 100 mg b.i.d. p.o. (i.v. in case of severe disease) | 7-14 days | (5, 6, 21, 38, 39, 61) |
| 2. doxycycline | 200 mg in single or two doses p.o. | one day | (5, 6) | |
| 3. fluoroquinolone | ofloxacin 200 mg b.i.d. p.o. | 10-14 days | (7, 19, 24) | |
| ciprofloxacin 500 mg b.i.d. p.o. | 10-14 days | (24, 50, 62) | ||
| 4. chloramphenicol | 500mg every 6 hours | 7-14 days | ||
| spotted fever group rickettsiosis in child of less than 8 years old | 1. doxycycline | 4 mg/Kg/day in two doses p.o. (no more than 200mg) | one day | (5, 6) |
| 2. macrolide | josamycin 50 mg/Kg/day b.i.d. p.o. | 7 days | (5) | |
| azithromycin 10 mg/Kg/day p.o. | 3 days | (38) | ||
| 3. chloramphenicol | 500mg every 6 hours | 7-14 days |
R. heilongjiangensis, R. massiliae, R. philipii, R. raoultii, and R. monacensis. The geographic distribution of some of the human pathogenic species has also been further described. The first-line treatment of these rickettsial diseases remains based on tetracyclines, including in young children with severe diseases. In contrast, the fluoroquinolones are no longer considered a safe alternative in patients involved with Mediterranean spotted fever, and should be used with caution for treatment of other spotted fevers.
What's New
Dubourg G, et al. Scalp eschar and neck lymphadenopathy after tick bite: an emerging syndrome with multiple causes. Eur J Clin Microbiol Infect Dis 2014;33:1449-1456.
Raoult D. Emerging Rickettsioses Reach the United States. Clin Infect Dis. 2010 Jul 1;51121-2.